Buloxibutid is an investigational new drug that is being evaluated to treat COVID-19 infections.[1] It is an angiotensin II receptor type 2 agonist.[2]
Clinical data | |
---|---|
Other names | VP-01 |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
ChEMBL | |
Chemical and physical data | |
Formula | C23H29N3O4S2 |
Molar mass | 475.62 g·mol−1 |
3D model (JSmol) | |
| |
|
References
edit- ^ "Buloxibutid - Vicore Pharma". AdisInsight. Springer Nature Switzerland AG.
- ^ Rein-Hedin E, Sjöberg F, Ganslandt C, Skoog J, Zachrisson H, Bengtsson T, et al. (February 2024). "Utilizing venous occlusion plethysmography to assess vascular effects: A study with buloxibutid, an angiotensin II type 2 receptor agonist". Clinical and Translational Science. 17 (2): e13735. doi:10.1111/cts.13735. PMC 10859786. PMID 38344891.